JPMorgan downgraded Hamilton Lane to Neutral from Overweight with an unchanged price target of $115. Hamilton Lane’s stock price has recovered, and the shares are now more appropriately valued, the analyst tells investors in a research note. Though the firm sees upside still in the shares longer term and remains positive on the company, it sees tactical investment opportunities more attractive elsewhere in the near term.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HLNE:
- HCAP Partners leads formation of PAX Health
- PAX Health Emerges as a Leading Force in Behavioral Health with the Strategic Acquisitions of Three Leading North-East-Based Companies
- Hamilton Lane 1.92M share Spot Secondary priced at $109.00
- Hamilton Lane 1.92M share Spot Secondary; price range $109.00-$110.00
- Hamilton Lane announces offering of 1.92M shares of Class A common stock
